A hepatitis B-vírus lamivudinrezisztens mutánsainak meghatározása.

Translated title of the contribution: Determination of the lamivudine-resistant mutants of hepatitis B virus

Judit Gervain, Istvánné Papp, Mihály Csöndes, Elemér Nemesánszky, I. Rácz, Pál Ribiczey, L. Telegdy, István Tornai, György Weisz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

INTRODUCTION: In addition to interferon, lamivudine is the other widely used antiviral agent in the therapy of chronic hepatitis B. This nucleoside analogue inhibits the RNA-dependent DNA polimerase and the reverse transcription by integrating in the viral DNA, which results in the secondary suppression of viral protein synthesis and replication of HBV. It has numerous advantages such as effective viral inhibition, mild side effects and the possibility of oral administration; on the other hand it poses the problem of time-correlated appearance of lamivudine resistant mutants during therapy. AIMS: In the Virusserology Laboratory of the Department I. Internal Medicine, Szent György Hospital, Székesfehérvár, detection and type determination of the therapy resistant mutants in the C and B domains of HBV DNA polimerase gene has been carried out the for one year. In this paper, the authors review the molecular biological background of lamivudine resistance and summarise the applied test methodologies and the early results. PATIENTS: Six-month and/or 12-, 18-month samples of 18 chronic hepatitis B patients (4 women/14 men) treated in seven Hepatology Centres in Hungary were analysed. METHODOLOGY: Mutants of codons 528, 552, and 555 in the HBV polimerase gene were determined by nested polimerase chain reaction and reverse hybridisation. RESULTS: M528, V552, I552 and I555 mutants in different variations could be detected in ten out of 18 patients. CONCLUSIONS: Nowadays, drug therapy is the only treatment option used for the therapy of early and progressed chronic hepatitis B in Hungary. This new diagnostic technique was introduced to clarify the background of ineffective lamivudine therapy. Therapy resistance can occur due to the lack of reaction or the appearance of the special, therapy resistant mutants of the virus. Detection of these YMDD mutants together with the clinical picture and the biochemical and virological parameters can help in forming a decision about cessation of lamivudine therapy or application of a new drug.

Original languageHungarian
Pages (from-to)1251-1256
Number of pages6
JournalOrvosi Hetilap
Volume144
Issue number25
Publication statusPublished - Jun 22 2003

Fingerprint

Lamivudine
Hepatitis B virus
Chronic Hepatitis B
Therapeutics
Hungary
DNA
Viral DNA
Viral Proteins
Gastroenterology
Internal Medicine
Nucleosides
Codon
Interferons
Genes
Reverse Transcription
Antiviral Agents
Oral Administration
RNA
Viruses
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gervain, J., Papp, I., Csöndes, M., Nemesánszky, E., Rácz, I., Ribiczey, P., ... Weisz, G. (2003). A hepatitis B-vírus lamivudinrezisztens mutánsainak meghatározása. Orvosi Hetilap, 144(25), 1251-1256.

A hepatitis B-vírus lamivudinrezisztens mutánsainak meghatározása. / Gervain, Judit; Papp, Istvánné; Csöndes, Mihály; Nemesánszky, Elemér; Rácz, I.; Ribiczey, Pál; Telegdy, L.; Tornai, István; Weisz, György.

In: Orvosi Hetilap, Vol. 144, No. 25, 22.06.2003, p. 1251-1256.

Research output: Contribution to journalArticle

Gervain, J, Papp, I, Csöndes, M, Nemesánszky, E, Rácz, I, Ribiczey, P, Telegdy, L, Tornai, I & Weisz, G 2003, 'A hepatitis B-vírus lamivudinrezisztens mutánsainak meghatározása.', Orvosi Hetilap, vol. 144, no. 25, pp. 1251-1256.
Gervain J, Papp I, Csöndes M, Nemesánszky E, Rácz I, Ribiczey P et al. A hepatitis B-vírus lamivudinrezisztens mutánsainak meghatározása. Orvosi Hetilap. 2003 Jun 22;144(25):1251-1256.
Gervain, Judit ; Papp, Istvánné ; Csöndes, Mihály ; Nemesánszky, Elemér ; Rácz, I. ; Ribiczey, Pál ; Telegdy, L. ; Tornai, István ; Weisz, György. / A hepatitis B-vírus lamivudinrezisztens mutánsainak meghatározása. In: Orvosi Hetilap. 2003 ; Vol. 144, No. 25. pp. 1251-1256.
@article{9bd27a7011624dc38770342b7cd7a0f7,
title = "A hepatitis B-v{\'i}rus lamivudinrezisztens mut{\'a}nsainak meghat{\'a}roz{\'a}sa.",
abstract = "INTRODUCTION: In addition to interferon, lamivudine is the other widely used antiviral agent in the therapy of chronic hepatitis B. This nucleoside analogue inhibits the RNA-dependent DNA polimerase and the reverse transcription by integrating in the viral DNA, which results in the secondary suppression of viral protein synthesis and replication of HBV. It has numerous advantages such as effective viral inhibition, mild side effects and the possibility of oral administration; on the other hand it poses the problem of time-correlated appearance of lamivudine resistant mutants during therapy. AIMS: In the Virusserology Laboratory of the Department I. Internal Medicine, Szent Gy{\"o}rgy Hospital, Sz{\'e}kesfeh{\'e}rv{\'a}r, detection and type determination of the therapy resistant mutants in the C and B domains of HBV DNA polimerase gene has been carried out the for one year. In this paper, the authors review the molecular biological background of lamivudine resistance and summarise the applied test methodologies and the early results. PATIENTS: Six-month and/or 12-, 18-month samples of 18 chronic hepatitis B patients (4 women/14 men) treated in seven Hepatology Centres in Hungary were analysed. METHODOLOGY: Mutants of codons 528, 552, and 555 in the HBV polimerase gene were determined by nested polimerase chain reaction and reverse hybridisation. RESULTS: M528, V552, I552 and I555 mutants in different variations could be detected in ten out of 18 patients. CONCLUSIONS: Nowadays, drug therapy is the only treatment option used for the therapy of early and progressed chronic hepatitis B in Hungary. This new diagnostic technique was introduced to clarify the background of ineffective lamivudine therapy. Therapy resistance can occur due to the lack of reaction or the appearance of the special, therapy resistant mutants of the virus. Detection of these YMDD mutants together with the clinical picture and the biochemical and virological parameters can help in forming a decision about cessation of lamivudine therapy or application of a new drug.",
author = "Judit Gervain and Istv{\'a}nn{\'e} Papp and Mih{\'a}ly Cs{\"o}ndes and Elem{\'e}r Nemes{\'a}nszky and I. R{\'a}cz and P{\'a}l Ribiczey and L. Telegdy and Istv{\'a}n Tornai and Gy{\"o}rgy Weisz",
year = "2003",
month = "6",
day = "22",
language = "Hungarian",
volume = "144",
pages = "1251--1256",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "25",

}

TY - JOUR

T1 - A hepatitis B-vírus lamivudinrezisztens mutánsainak meghatározása.

AU - Gervain, Judit

AU - Papp, Istvánné

AU - Csöndes, Mihály

AU - Nemesánszky, Elemér

AU - Rácz, I.

AU - Ribiczey, Pál

AU - Telegdy, L.

AU - Tornai, István

AU - Weisz, György

PY - 2003/6/22

Y1 - 2003/6/22

N2 - INTRODUCTION: In addition to interferon, lamivudine is the other widely used antiviral agent in the therapy of chronic hepatitis B. This nucleoside analogue inhibits the RNA-dependent DNA polimerase and the reverse transcription by integrating in the viral DNA, which results in the secondary suppression of viral protein synthesis and replication of HBV. It has numerous advantages such as effective viral inhibition, mild side effects and the possibility of oral administration; on the other hand it poses the problem of time-correlated appearance of lamivudine resistant mutants during therapy. AIMS: In the Virusserology Laboratory of the Department I. Internal Medicine, Szent György Hospital, Székesfehérvár, detection and type determination of the therapy resistant mutants in the C and B domains of HBV DNA polimerase gene has been carried out the for one year. In this paper, the authors review the molecular biological background of lamivudine resistance and summarise the applied test methodologies and the early results. PATIENTS: Six-month and/or 12-, 18-month samples of 18 chronic hepatitis B patients (4 women/14 men) treated in seven Hepatology Centres in Hungary were analysed. METHODOLOGY: Mutants of codons 528, 552, and 555 in the HBV polimerase gene were determined by nested polimerase chain reaction and reverse hybridisation. RESULTS: M528, V552, I552 and I555 mutants in different variations could be detected in ten out of 18 patients. CONCLUSIONS: Nowadays, drug therapy is the only treatment option used for the therapy of early and progressed chronic hepatitis B in Hungary. This new diagnostic technique was introduced to clarify the background of ineffective lamivudine therapy. Therapy resistance can occur due to the lack of reaction or the appearance of the special, therapy resistant mutants of the virus. Detection of these YMDD mutants together with the clinical picture and the biochemical and virological parameters can help in forming a decision about cessation of lamivudine therapy or application of a new drug.

AB - INTRODUCTION: In addition to interferon, lamivudine is the other widely used antiviral agent in the therapy of chronic hepatitis B. This nucleoside analogue inhibits the RNA-dependent DNA polimerase and the reverse transcription by integrating in the viral DNA, which results in the secondary suppression of viral protein synthesis and replication of HBV. It has numerous advantages such as effective viral inhibition, mild side effects and the possibility of oral administration; on the other hand it poses the problem of time-correlated appearance of lamivudine resistant mutants during therapy. AIMS: In the Virusserology Laboratory of the Department I. Internal Medicine, Szent György Hospital, Székesfehérvár, detection and type determination of the therapy resistant mutants in the C and B domains of HBV DNA polimerase gene has been carried out the for one year. In this paper, the authors review the molecular biological background of lamivudine resistance and summarise the applied test methodologies and the early results. PATIENTS: Six-month and/or 12-, 18-month samples of 18 chronic hepatitis B patients (4 women/14 men) treated in seven Hepatology Centres in Hungary were analysed. METHODOLOGY: Mutants of codons 528, 552, and 555 in the HBV polimerase gene were determined by nested polimerase chain reaction and reverse hybridisation. RESULTS: M528, V552, I552 and I555 mutants in different variations could be detected in ten out of 18 patients. CONCLUSIONS: Nowadays, drug therapy is the only treatment option used for the therapy of early and progressed chronic hepatitis B in Hungary. This new diagnostic technique was introduced to clarify the background of ineffective lamivudine therapy. Therapy resistance can occur due to the lack of reaction or the appearance of the special, therapy resistant mutants of the virus. Detection of these YMDD mutants together with the clinical picture and the biochemical and virological parameters can help in forming a decision about cessation of lamivudine therapy or application of a new drug.

UR - http://www.scopus.com/inward/record.url?scp=0141499087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141499087&partnerID=8YFLogxK

M3 - Article

VL - 144

SP - 1251

EP - 1256

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 25

ER -